Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 4Recurrence 2Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Klatskin Tumor 1Hematologic Neoplasms 1Hematologic Diseases 1Fallopian Tube Neoplasms 1Disease Progression 1Disease 1Cholangiocarcinoma 1Breast Neoplasms 1Blood Protein Disorders 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 112Cisplatin 76Oxaliplatin 44pembrolizumab 34Fluorouracil 32Capecitabine 30durvalumab 27Leucovorin 26lenvatinib 23Magnetic Resonance Spectroscopy 15Irinotecan 14Nivolumab 12Biopsy 12Albumin-Bound Paclitaxel 12tislelizumab 11Specimen Handling 11Radiofrequency Ablation 11Drug Therapy 11pemigatinib 10apatinib 10Taxes 10Floxuridine 10130-nm albumin-bound paclitaxel 10Radiotherapy 9Bevacizumab 9Platinum 8Folfox protocol 8Carboplatin 81,2-diaminocyclohexaneplatinum II citrate 8tremelimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cholangiocarcinoma × ricolinostat × Clear all
NCT02856568 2017-05-30

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡